» Articles » PMID: 28451791

Tumor-associated Fibrosis As a Regulator of Tumor Immunity and Response to Immunotherapy

Overview
Date 2017 Apr 29
PMID 28451791
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated fibrosis is characterized by unchecked pro-fibrotic and pro-inflammatory signaling. The components of fibrosis including significant numbers of cancer-associated fibroblasts, dense collagen deposition, and extracellular matrix stiffness, are well appreciated regulators of tumor progression but may also be critical regulators of immune surveillance. While this suggests that the efficacy of immunotherapy may be limited in highly fibrotic cancers like pancreas, it also suggests a therapeutic opportunity to target fibrosis in these tumor types to reawaken anti-tumor immunity. This review discusses the mechanisms by which fibrosis might subvert tumor immunity and how to overcome these mechanisms.

Citing Articles

The multi-faceted immune modulatory role of S100A4 in cancer and chronic inflammatory disease.

Wong T, Kang R, Yun K Front Immunol. 2025; 16:1525567.

PMID: 40078995 PMC: 11897520. DOI: 10.3389/fimmu.2025.1525567.


Unveiling the link between chronic inflammation and cancer.

Tripathi S, Sharma Y, Kumar D Metabol Open. 2025; 25:100347.

PMID: 39876904 PMC: 11772974. DOI: 10.1016/j.metop.2025.100347.


High levels of fibrotic tumor components are associated with recurrence and intratumoral immune status in advanced colorectal cancer patients.

Dorjkhorloo G, Shiraishi T, Erkhem-Ochir B, Sohda M, Okami H, Yamaguchi A Sci Rep. 2024; 14(1):30735.

PMID: 39730445 PMC: 11680924. DOI: 10.1038/s41598-024-80489-w.


Targeting extracellular matrix stiffness for cancer therapy.

Feng X, Cao F, Wu X, Xie W, Wang P, Jiang H Front Immunol. 2024; 15():1467602.

PMID: 39697341 PMC: 11653020. DOI: 10.3389/fimmu.2024.1467602.


Cancer-associated fibroblasts: heterogeneity, tumorigenicity and therapeutic targets.

Lv K, He T Mol Biomed. 2024; 5(1):70.

PMID: 39680287 PMC: 11649616. DOI: 10.1186/s43556-024-00233-8.


References
1.
Jiang H, Hegde S, Knolhoff B, Zhu Y, Herndon J, Meyer M . Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016; 22(8):851-60. PMC: 4935930. DOI: 10.1038/nm.4123. View

2.
Gilkes D, Chaturvedi P, Bajpai S, Wong C, Wei H, Pitcairn S . RETRACTED: Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res. 2013; 73(11):3285-96. PMC: 3674184. DOI: 10.1158/0008-5472.CAN-12-3963. View

3.
Hajime M, Shuichi Y, Makoto N, Masanori Y, Ikuko K, Atsushi K . Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer. 2007; 120(12):2704-9. DOI: 10.1002/ijc.22349. View

4.
Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J . Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One. 2013; 8(2):e55146. PMC: 3570471. DOI: 10.1371/journal.pone.0055146. View

5.
Kalluri R . The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16(9):582-98. DOI: 10.1038/nrc.2016.73. View